San Diego, CA — Binding Site’s Immunologicals Group is pleased to announce the addition of eight new recombinant antigens to its broad offering of products for in-vitro diagnostic (IVD) manufacturing and research applications. The recombinant Parvovirus NS1; Parvovirus VP1; Parvovirus VP2; Parvovirus VP2-VLP; Parvovirus PepA (VP1 unique); Parvovirus PepB (VP2 C-term); Parvovirus PepC (VP1 N-term); and Parvovirus PepD (VP1 C-term) have all been expressly designed for use as an integral component within solid phase enzyme immunoassay (EIA) test procedures, including ELISA.
All of these antigens are sourced from an E. coli derived recombinant protein and exhibit exceptional purity levels as a result of unique chromatography techniques. Plus, these Parvo Virus antigens demonstrate exceptional lot-to-lot consistencies, while displaying the highest degrees of activity and specificity. They all feature an outstanding shelf life stability claim of ten years from the date of manufacture and are offered in a standard sized 1.0mg filled vial, with larger, bulk configurations also being available. Test samples are also available for evaluation purposes. As such, the availability of these antigens is certain to benefit the needs of biopharmaceutical, clinical, and life science researchers, as well as manufacturers of IVD test kits.
Binding Site’s Immunologicals Group serves the in-vitro diagnostic (IVD) manufacturing and clinical/life-science research markets with a comprehensive line of innovative products. For additional information, contact The Binding Site, Inc. at 6730 Mesa Ridge Road, San Diego, CA 92121 USA. Phone: 800-633-4484; FAX: 858-453-9189; Email: email@example.com. Please visit our website at www.immunologicals.com.